The Cannigma

JUNE 25, 2022

Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products. Qualifying conditions include chronic pain, multiple sclerosis, spasticity, chemo-induced nausea, and treatment-resistant epilepsy. Poland’s medical cannabis program.

Legalization 108

Legalization Supply Chain Chronic Pain Tincture 108

SpeedWeed

JUNE 15, 2021

The British cannabis pharmaceutical company takes home an award that demonstrates how important cannabis has been to the British economy for over 20 years—but also how much it so far has been reserved, as an industry, and as a drug, for the elite. GW Pharmaceuticals was just awarded a so-called “ Queen’s Prize for Innovation.” .

Pharmaceutical 40

Pharmaceutical Chronic Pain Epilepsy Patients 40

Veriheal

NOVEMBER 10, 2020

The experiment will allow participating companies to import cannabis and the companies who wish to participate in the experiment will be obliged to give participants free medical cannabis which has to comply with the pharmaceutical standards and good manufacturing practice. .

Chronic Pain 90

Chronic Pain Pharmaceutical Patients Epilepsy 90

CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. This statistic accounts for medicines treating patients with epilepsy, anxiety, depression, chronic pain, and other illnesses. This article has primarily offered a small dose of the pharmaceutical side of the medical cannabis market in Latin America.

Access 89

Access Patients Pharmaceutical Education 89

Veriheal

MAY 17, 2021

Please don’t further the lie by voting for any form of legalization beyond the pharmaceutical remedies already available under state law.” That is perhaps the biggest lie that is being perpetuated on the Alabama public today. ” State Doctors Oppose Legalization in Alabama.

Legalization 93

Legalization Pharmaceutical Therapy Chronic Pain 93

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

SEPTEMBER 6, 2021

GW Pharmaceuticals. GW Pharmaceuticals. Chronic Pain. Looking forward, the publisher expects the global medical cannabis market to grow at a CAGR of 15.3% during 2021-2026. Companies Mentioned. Canopy Growth Corporation. Aurora Cannabis Inc. Aphria Inc. MedReleaf Corporation. Insys Therapeutics Inc. Cara Therapeutics Inc.

Chronic Pain 66

Chronic Pain Research and Development Clinical Trials Epilepsy 66

Veriheal

AUGUST 9, 2023

CBD, Trema micrantha, and the Study’s Significance CBD means cannabidiol , one of over a hundred compounds in the cannabis plant, and is widely celebrated as a potential treatment for a long list of health concerns, including chronic pain , epilepsy , i nsomnia , anxiety , and skin allergy.

CBD 96

CBD Cannabinoids THC Extraction 96

Cannabis Law Report

JANUARY 4, 2022

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. Virpax”), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Pharmaceutical 40

Pharmaceutical Research and Development Chronic Pain Epilepsy 40

Veriheal

JULY 21, 2022

On July 1, the process of procuring pharmaceutical-approved cannabis was simplified for individuals residing across the state, where the first licensed medical marijuana dispensary opened its doors in August 2020. Chronic pain. Epilepsy / seizure disorders. Amyotrophic Lateral Sclerosis (ALS) . Crohn’s disease.

Access 105

Access Dispensary Patients Programs 105

Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

United Patients Group

FEBRUARY 2, 2023

The ECS has been studied for its role in many diseases including cancer , epilepsy, chronic pain and multiple sclerosis (MS). For example, if your insomnia is due to pain or anxiety, cannabis can help you get some restful sleep. antibiotics).

Blood Pressure 105

Blood Pressure Sleep Chronic Pain Digestion 105

Veriheal

JANUARY 12, 2023

The law also permits the agricultural production of cannabis and hemp for industrial purposes, with a heavy emphasis on pharmaceutical crops. . Approximately 3,000 patients who suffer from debilitating conditions like chronic pain and epilepsy will partake in the project, which is due to end in March 2023.

Medicine 97

Medicine Chronic Pain Consumption Cannabis 97

PrestoDoctor

OCTOBER 13, 2023

Marinol, also known as Dronabinol, is a medication used to treat a variety of conditions, including nausea and vomiting caused by chemotherapy, loss of appetite and weight loss in people with HIV/AIDS, as well as chronic pain. However, unlike marijuana, Marinol is a FDA-approved pharmaceutical drug.

THC 98

THC Chronic Pain Treatment Conditions 98

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Cannabis Law Report

DECEMBER 28, 2021

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 40

Pharmaceutical Therapy Clinical Trials Chronic Pain 40

Cannabis Law Report

OCTOBER 5, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Media 40

Veriheal

DECEMBER 28, 2021

Chronic pain. For example, pharmaceutical-grade cannabis is being sold across the fast-evolving retail pharmacy landscape. Consequently, the scientific community was astounded to discover that the ground-grown plant may offer relief from widespread medical conditions , including: AIDS. Amyotrophic lateral sclerosis (ALS).

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Cannabis Law Report

JUNE 20, 2019

Chronic pain. Medical cannabis is known to possess pain-relieving properties. Thus, many people often use it to relieve themselves of chronic pain, muscle pain, and pain in the joints. Chronic pain is the primary cause of disability in many people worldwide.

History 67

History Medicine Chronic Pain Conditions 67

Cannabis Law Report

JUNE 7, 2019

The farm is run by GW Pharmaceuticals, where around two million cannabis plants have been produced since its opening in 1998. Those suffering from epilepsy, nausea and chronic pain due to chemotherapy are now given the option to get the drug on prescription, reports The Mirror . Kent Live Report.

Chronic Pain 40

Chronic Pain Epilepsy Legalization Pharmaceutical 40

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. We continue to enhance our product pipeline, and because of our unique delivery technologies we have expanded our targeted indications beyond pain to include Central Nervous System (CNS) disorders and anti-viral indications. “Our

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

MAY 9, 2022

The company is following in the footsteps of GW Pharmaceuticals, a trailblazer that developed the first cannabis-based medicine to be licensed in the UK in 2010, Sativex for multiple sclerosis, which costs about £2,000 a year. However, NHS prescribing of the mouth spray remains very limited and varies across the country.

Chronic Pain 52

Chronic Pain Epilepsy Oil Pharmaceutical 52

Cannabis Law Report

SEPTEMBER 9, 2021

Medical cannabis is used for the treatment of various chronic conditions, such as Parkinson’s disease, Alzheimer’s disease, arthritis, cancer, depression, anxiety, epilepsy, and other neurological conditions. Chronic Pain. GW Pharmaceuticals, PLC. Segment Dashboard. Medical Use. Depression and Anxiety.

Recreational 73

Recreational Hemp THC Legalization 73

Cannabis Law Report

SEPTEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. About Virpax Pharmaceuticals.

Epilepsy 40

Epilepsy Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

APRIL 22, 2019

Mr Plamandon said he successfully brought Thai-prescribed cannabis products into WA to treat his chronic pain on April 8. million chronic pain sufferers were predicted to get access to the drug in 2019. million chronic pain sufferers were predicted to get access to the drug in 2019. overseas.

Chronic Pain 10

Chronic Pain Medicine Conditions Access 10

Cannabis Law Report

SEPTEMBER 28, 2021

However, it is a whole different story if someone suffers from serious and chronic pain. In most situations, it is related to another chronic condition that cannot be cured quickly or at all. In this case, the patient needs to look for the best ways to treat pain and improve their life quality. Acupuncture. CBD Products.

Treatment 52

Treatment Chronic Pain Therapy Tincture 52

MMJ Recs

FEBRUARY 18, 2024

These may include chronic pain, nausea and vomiting related to chemotherapy, muscle spasms, seizures, and mental health disorders. One of the most well-known applications is pain relief, particularly for chronic pain, arthritis, and neuropathic pain.

Chronic Pain 52

Chronic Pain Marijuana Epilepsy Research and Development 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Chronic Pain 40

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

MARCH 25, 2020

Panaxia’s CBD-rich oil is targeted at specific group of patients that require a miniscule dose of THC (categories C20, C24) among whom is a large group of children suffering from epilepsy or autism spectrum disorder (ASD). About Panaxia Israel. Panaxia was founded by Dr. Dadi Segal , Dr. Eran Goldberg and Assi Rotbart , LL.b,

Oil 45

Oil Pharmaceutical Epilepsy Extraction 45

Cannabis Law Report

NOVEMBER 18, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Business Chronic Pain 40

Cannabis Law Report

DECEMBER 29, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain CBD 40

Cannabis Law Report

NOVEMBER 23, 2021

The products to be manufactured at the facility aren’t specified, but will be used for managing chronic pain, epilepsy, multiple sclerosis, and pain associated with palliative care. The subject land is zoned RU1 Primary Production. Further information on the proposed project can be found here.

Chronic Pain 52

Chronic Pain Epilepsy Environment Pharmaceutical 52